Ferrum Lek® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Lek d.d., Slovenia) + MALTOFER® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Vifor S.A., Switzerland)
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Mild and Moderate Iron-deficiency Anaemia
Conditions
Mild and Moderate Iron-deficiency Anaemia
Trial Timeline
Jun 27, 2019 → Jun 18, 2020
NCT ID
NCT03993288About Ferrum Lek® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Lek d.d., Slovenia) + MALTOFER® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Vifor S.A., Switzerland)
Ferrum Lek® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Lek d.d., Slovenia) + MALTOFER® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Vifor S.A., Switzerland) is a phase 3 stage product being developed by Sandoz Group for Mild and Moderate Iron-deficiency Anaemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03993288. Target conditions include Mild and Moderate Iron-deficiency Anaemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03993288 | Phase 3 | Completed |
Competing Products
20 competing products in Mild and Moderate Iron-deficiency Anaemia